Sun Pharma acquires Organon

Sun Pharmaceutical Industries is set to acquire Organon & Co., a company spun off from Merck & Co. in 2021, for $11.75 billion. This acquisition, among the largest in 2026, signals a significant expansion in Sun Pharma’s capabilities within women’s health, biosimilars, and established branded medicines. By purchasing Organon, Sun Pharma, which is primarily known for its generics business, aims to bolster its portfolio in the pharmaceuticals sector.

Organon, with a product line of over 70 offerings across women's health and general medicines, including biosimilars, reported revenues of $6.2 billion in 2025. The company operates six manufacturing facilities located in the European Union and emerging markets. This acquisition aligns with Sun Pharma's strategy to grow its Innovative Medicines business, which focuses on dermatology, oncology, and ophthalmology. The deal would increase the combined company’s revenue to $12.4 billion, with Innovative Medicines accounting for 27% of Sun Pharma's sales.

This acquisition is a strategic move for Sun Pharma, following its recent acquisitions of Concert Pharmaceuticals and Checkpoint Therapeutics for $576 million and $418 million, respectively. The Concert Pharmaceuticals acquisition secured Sun Pharma Leqselvi, aimed at treating alopecia areata, while buying Checkpoint Therapeutics added Unloxcyt, used for treating advanced cutaneous squamous cell carcinoma. Through these investments, Sun Pharma is augmenting its product offerings beyond generics, particularly targeting its expansion in specialties.

The acquisition of Organon is expected to propel Sun Pharma into a leading position as a top three player in women's health and the seventh in biosimilars globally. This expansion is crucial as the pharmaceutical market sees a growing demand for innovative treatments in both sectors. The competitive landscape continues to evolve with major pharmaceutical companies eyeing strategic mergers and acquisitions. Sun Pharma's acquisition positions it as a company extending beyond generics to a more diversified pharmaceutical portfolio.

The transaction has already received approval from the boards of both companies, though it remains contingent on customary closing conditions, including regulatory approvals and Organon stockholder consent. The deal is projected to conclude in early 2027, subject to these conditions. The integration of Organon into Sun Pharma's operations will be closely watched by industry observers for its impact on market dynamics and competitive positioning.